SurModics Inc (SRDX)

[DewDiligence]

>If a positive can come from this it may be opening up T/A to use in combination with other drugs.<

The best decision, IMHO, would be to discontinue the entire InnoRx program because it’s no longer commercially attractive.

I don’t blame SRDX unduly for this; at the time SRDX acquired InnoRx, it was not as clear as it is today that low-cost off-label Avastin would render this market untenable for new premium-priced products.